Last reviewed · How we verify
Placebo comparator dosing
Placebo comparator dosing is a Small molecule drug developed by Pfizer. It is currently FDA-approved.
A placebo comparator dosing regimen contains no active pharmaceutical ingredient and serves as a control arm in clinical trials to measure the effect of an investigational drug against baseline or standard care.
AZD4076 is a small molecule being studied in clinical trials for various conditions, including Non-alcoholic Steatohepatitis (NASH), Diabetic Neuropathies, and Diabetes Mellitus, Type 2. In the clinical trial NCT02612662, AZD4076 was compared to a placebo in a single-blind, placebo-controlled study to assess its safety, tolerability, and pharmacokinetics in healthy male subjects.
At a glance
| Generic name | Placebo comparator dosing |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo comparators are inert formulations used in randomized controlled trials to establish the efficacy and safety of a test drug by comparing outcomes in the treatment group versus the control group receiving placebo. The placebo effect and natural disease progression are accounted for through this comparison, allowing researchers to isolate the true pharmacological benefit of the investigational agent.
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (PHASE3)
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection (PHASE2)
- Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo comparator dosing CI brief — competitive landscape report
- Placebo comparator dosing updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Placebo comparator dosing
What is Placebo comparator dosing?
How does Placebo comparator dosing work?
Who makes Placebo comparator dosing?
What development phase is Placebo comparator dosing in?
Related
- Manufacturer: Pfizer — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing